期刊文献+

缬沙坦预防阵发性房颤复发的临床研究 被引量:6

Clinical Study of Prevention of Recurrence of Paroxysmal Atrial Fibrillation with Valsartan
暂未订购
导出
摘要 目的:评价缬沙坦在预防阵发性房颤复发中的疗效。方法:阵发性、症状性房颤患者91例,恢复窦性心律后,随机分为对照组45例,单纯口服胺碘酮;治疗组46例,在此基础上加服缬沙坦每天80mg,随访观察1年。结果:治疗组窦性心律维持率明显高于对照组(81.8%VS62.8%,P<0.05),左房内经明显小于对照组[(35.10±10.21)mmVS(41.82±11.60)mm],差异均有显著意义。结论:缬沙坦联合胺碘酮对阵发性房颤复律后预防房颤复发维持窦性心律作用明显优于单用胺碘酮治疗,这与缬沙坦抑制肾素血管紧张素系统,降低心脏负荷,抑制心房电重构及结构重构有关,且无明显不良反应。 Objective:To evaluate the valsartan in the prevention of recurrence of paroxysmal atrial fibrillation efficacy.Methods: Paroxysmal,91 patients with symptomatic atrial fibrillation and restore sinus rhythm were randomly divided into control group,45 patients of oral amiodarone in the treatment group 46 patients with additional service on this basis,a daily valsartan 80rag,were followed up for one year. Results:The treatment group was significantly higher than the maintenance of sinus rhythm (81.8%VS62.8%,P〈0.05),left the room by significantly less than the control group[(35.10±10.21)mmVS(41.82±11.60)mm].There were significant differences.Conelusion:Valsartan combined effect of amiodarone on atrial fibrillation after cardioversion of atrial fibrillation to prevent recurrence of the role of maintenance of sinus rhythm significantly better than treatment with amiodarone,which inhibit the renin-angiotensin system with valsartan,reduced cardiac stress,inhibition of atrial electrical remodeling and structural remodeling related, and no obvious adverse reactions.
作者 黄国定
出处 《中国医药导刊》 2011年第1期93-94,共2页 Chinese Journal of Medicinal Guide
关键词 缬沙坦 心房颤动 Paroxysmal atrial fibrillation Sinus rhythm Valsartan
  • 相关文献

参考文献5

二级参考文献49

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1408
  • 2黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:270
  • 3裴德安,李莉,徐志云,邹良建,张宝仁,黄盛东,郝家骅,王志农.心房颤动患者心房组织醛固酮水平与心房结构重构的相关性研究[J].第二军医大学学报,2007,28(2):170-174. 被引量:9
  • 4Wachtell K,Lehto M, Hornestam B, et al. Losartan reduces the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy:the LIFE studv[J]. Eur Heart J, 2003, 24:504.
  • 5Finkielstein D,Schweitzer P. Role of angiotensin-oonverting enzyme inhibitors in the prevention of atrial fibrillation[J]. Am J Cardiol,2004,93:734-736.
  • 6Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan:resuhs from the CHARM study[J]. J Am Coll Cardiol,2004,43 ( suppl A ) : 222 A.
  • 7Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan:resuhs from the CHARM study[abstract][J]. J Am Coll Cardiol,2004,43 ( suppl A ) :222 A.
  • 8Teo K,Yusuf S,Anderson C,et al.Rationale ,design,and baseline characteristics of 2 large,simple randomized trials evaluating telmisartan,ramipril and their combination in high-risk patients:The ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment in ACE intolerant subjects with cardiovascular disease[J].Am Heart J,2004,148:52-61.
  • 9Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjuvent therapy in patients with persistent atrial fibrillation [J]. Am Heart J ,2004,147 : 823-827.
  • 10Kumagai K, Nakashima H, Urata H ,et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation [J]. J Am Coll Cardiol,2003,41:2197-2204.

共引文献108

同被引文献39

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部